Given that the SOD3 protein itself exerts specific protection against TNF-α but not IFN-γ in IOs, it would be interesting to evaluate the benefits of control- and SOD3-MSCs against various IBD-mimicking combinations such as IL1-β and flagellin, and to explore the therapeutic factors responsible for each stimulus. This evidence concerns the gene TNF and inflammatory bowel disease.